Compendium of projects in the European nanosafety cluster

This is the third edition of the compendium. It documents the status of important projects on nanomaterial toxicity and exposure monitoring, integrated risk management, research infrstructure and coordination and support activities. The compendium is not intended to be a guidance document for human health and environmental safety management of nanotechnologies, as such guidance documents already exist and are widely available. Neither is the compendium intended to be a medium for the publication of scientific papers and research results, as this task is covered by scientific conferences and the reviewed press. The compendium aims to bring researchers closer together and show them the potential for synergy in their work. It is a means to establish links and communication between them during the actual research phase and well before the publication of their results. It thus focuses on the communication of projects' strategic aims, extensively covers specific work objectives and the methods used in research, and documents human capacities and available laboratory infrastructure. As such, the compendium supports collaboration on common goals and the joint elaboration of future plans, whilst compromising neither the potential for scientific publication, nor intellectual property rights. [Auteurs]]]> Nanoparticles ; Risk Assessment ; Risk Management ; Research ; eng oai:serval.unil.ch:BIB_0A1CD8E3E744 2023-07-29T01:16:12Z ehelvetica phdthesis urnserval <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"> https://serval.unil.ch/notice/serval:BIB_0A1CD8E3E744 25 ans d'hystérectomie élargie selon Wertheim-Meigs pour le carcinome du col utérin à Lausanne Koch, Nathalie Université de Lausanne, Faculté de médecine info:eu-repo/semantics/doctoralThesis phdthesis 2002 fre https://serval.unil.ch/resource/serval:BIB_0A1CD8E3E744.P001/REF.pdf http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_0A1CD8E3E7447 info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_0A1CD8E3E7447 info:eu-repo/semantics/restrictedAccess Restricted: indefinite embargo Copying allowed only for non-profit organizations https://serval.unil.ch/disclaimer application/pdf oai:serval.unil.ch:BIB_0A145DCFFCB1 2023-07-29T01:16:12Z openaire documents urnserval <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"> https://serval.unil.ch/notice/serval:BIB_0A145DCFFCB1 Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression. info:doi:10.1186/s13195-021-00805-8 info:eu-repo/semantics/altIdentifier/doi/10.1186/s13195-021-00805-8 info:eu-repo/semantics/altIdentifier/pmid/33766131 Clark, C. Lewczuk, P. Kornhuber, J. Richiardi, J. Maréchal, B. Karikari, T.K. Blennow, K. Zetterberg, H. Popp, J. info:eu-repo/semantics/article article 2021-03-25 Alzheimer's research &amp; therapy, vol. 13, no. 1, pp. 65 info:eu-repo/semantics/altIdentifier/eissn/1758-9193 <![CDATA[To assess the performance of plasma neurofilament light (NfL) and phosphorylated tau 181 (p-tau181) to inform about cerebral Alzheimer's disease (AD) pathology and predict clinical progression in a memory clinic setting. Plasma NfL and p-tau181, along with established cerebrospinal fluid (CSF) biomarkers of AD pathology, were measured in participants with normal cognition (CN) and memory clinic patients with cognitive impairment (mild cognitive impairment and dementia, CI). Clinical and neuropsychological assessments were performed at inclusion and follow-up visits at 18 and 36 months. Multivariate analysis assessed associations of plasma NfL and p-tau181 levels with AD, single CSF biomarkers, hippocampal volume, and clinical measures of disease progression. Plasma NfL levels were higher in CN participants with an AD CSF profile (defined by a CSF p-tau181/Aβ &lt;sub&gt;1-42&lt;/sub&gt; &gt; 0.0779) as compared with CN non-AD, while p-tau181 plasma levels were higher in CI patients with AD. Plasma NfL levels correlated with CSF tau and p-tau181 in CN, and with CSF tau in CI patients. Plasma p-tau181 correlated with CSF p-tau181 in CN and with CSF tau, p-tau181, Aβ &lt;sub&gt;1-42&lt;/sub&gt; , and Aβ &lt;sub&gt;1-42&lt;/sub&gt; /Aβ &lt;sub&gt;1-40&lt;/sub&gt; in CI participants. Compared with a reference model, adding plasma p-tau181 improved the prediction of AD in CI patients while adding NfL did not. Adding p-tau181, but not NfL levels, to a reference model improved prediction of cognitive decline in CI participants. Plasma NfL indicates neurodegeneration while plasma p-tau181 levels can serve as a biomarker of cerebral AD pathology and cognitive decline. Their predictive performance depends on the presence of cognitive impairment